389087-55-2

Upstream product

• 389087-52-9 3,7-anhydro-4-[(R)-3-benzyloxytetradecanoylamino]-2,4-dideoxy-6-O-diphenylphosphono-5-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-octonic acid benzyl ester 
• 135561-34-1 benzyl <2-<(R)-3-(benzyloxy)tetradecanamido>-2-deoxy-3-O-<(R)-3-(tetradecanoyloxy)tetradecanoyl>-α-D-glucopyranosyl>acetate 
• 389087-50-7 3,7-anhydro-4-[(R)-3-benzyloxytetradecanoylamino]-8-O-t-butyldimethylsilyl-2,4-dideoxy-5-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-octonic acid benzyl ester 
• 389087-51-8 3,7-anhydro-4-[(R)-3-benzyloxytetradecanoylamino]-8-O-t-butyldimethylsilyl-2,4-dideoxy-6-O-diphenylphosphono-5-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-octonic acid benzyl ester 

Relevant academic research and scientific papers

Synthesis and biological activity of 3,7-anhydro-2,4-dideoxy-4-[(R)-3-hydroxytetradecanoylamino]-6-O-phosphono- 5-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-octonic acid derivatives

D-Glucosaminylacetic acid derivatives (10, 11 and 12) of GLA-60 were synthesized to investigate the LPS-antagonistic activity toward human monoblastic U937 cells. Compounds 10 and 11 show weak LPS-antagonistic activity, but 12 shows both LPS-antagonistic and -agonistic activities, depending on the concentration.